Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Accounts Payables: 2013-2020

Historic Accounts Payables for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $1.3 million.

  • Larimar Therapeutics' Accounts Payables fell 61.77% to $1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $1.3 million, marking a year-over-year decrease of 61.77%. This contributed to the annual value of $3.5 million for FY2019, which is 1.42% down from last year.
  • Larimar Therapeutics' Accounts Payables amounted to $1.3 million in Q3 2020, which was down 43.80% from $2.3 million recorded in Q2 2020.
  • In the past 5 years, Larimar Therapeutics' Accounts Payables ranged from a high of $4.4 million in Q2 2017 and a low of $322,000 during Q1 2020.
  • Over the past 3 years, Larimar Therapeutics' median Accounts Payables value was $3.0 million (recorded in 2018), while the average stood at $2.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first spiked by 98.74% in 2018, then slumped by 89.80% in 2020.
  • Larimar Therapeutics' Accounts Payables (Quarterly) stood at $2.6 million in 2016, then grew by 17.42% to $3.0 million in 2017, then grew by 18.87% to $3.6 million in 2018, then dropped by 1.42% to $3.5 million in 2019, then slumped by 61.77% to $1.3 million in 2020.
  • Its Accounts Payables was $1.3 million in Q3 2020, compared to $2.3 million in Q2 2020 and $322,000 in Q1 2020.